StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.66−0.30 (-0.78%)

Close on Nov 20, 2026Market cap $27.92BP/E –Yield –

Roivant Sciences Arbutus Biopharma Corp. (ABUS) by Quarter

Arbutus Biopharma Corp. (ABUS) — Marketable Securities ($M)

Periods

Roivant Sciences Arbutus Biopharma Corp. (ABUS): $73.3M in Q2 FY2026, up 2.8% from a year earlier.

Latest, Q2 FY2026
73.3
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+2.8%
71.3 in Q2 FY2025
History
26 quarters
Since Q1 FY2020
Sources
20
Documents cited below

Where the Q2 FY2026 figure comes from

Source: Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗

Reported in ABUS Form 10-K / 10-Q (XBRL).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArbutus Biopharma Corp. (ABUS) — Marketable Securities ($M)Year on yearSource
Q2 FY2026CQ3 2026Sep 30, 202673.3+2.8%Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗
Q1 FY2026CQ2 2026Jun 30, 202673.5+21.0%Arbutus Biopharma Corp. Form 10-Q (filed 2026-08-12) ↗
Q4 FY2025CQ1 2026Mar 31, 202671.5-5.4%Arbutus Biopharma Corp. Form 10-Q (filed 2026-05-13) ↗
Q3 FY2025CQ4 2025Dec 31, 202573.5-14.9%Arbutus Biopharma Corp. Form 10-Q (filed 2026-11-10) ↗
Q2 FY2025CQ3 2025Sep 30, 202571.3-25.7%Arbutus Biopharma Corp. Form 10-Q (filed 2025-11-13) ↗
Q1 FY2025CQ2 2025Jun 30, 202560.7-23.4%Arbutus Biopharma Corp. Form 10-Q (filed 2025-08-06) ↗
Q4 FY2024CQ1 2025Mar 31, 202575.6-12.2%Arbutus Biopharma Corp. Form 10-Q (filed 2025-05-14) ↗
Q3 FY2024CQ4 2024Dec 31, 202486.3-13.5%Arbutus Biopharma Corp. Form 10-Q (filed 2025-11-13) ↗
Q2 FY2024CQ3 2024Sep 30, 202496.0-17.7%Arbutus Biopharma Corp. Form 10-Q (filed 2024-11-06) ↗
Q1 FY2024CQ2 2024Jun 30, 202479.2-36.8%Arbutus Biopharma Corp. Form 10-Q (filed 2024-08-08) ↗
Q4 FY2023CQ1 2024Mar 31, 202486.1-18.9%Arbutus Biopharma Corp. Form 10-Q (filed 2024-05-02) ↗
Q3 FY2023CQ4 2023Dec 31, 202399.7-14.1%Arbutus Biopharma Corp. Form 10-Q (filed 2024-11-06) ↗
Q2 FY2023CQ3 2023Sep 30, 2023117+5.4%Arbutus Biopharma Corp. Form 10-Q (filed 2023-11-07) ↗
Q1 FY2023CQ2 2023Jun 30, 2023125+21.8%Arbutus Biopharma Corp. Form 10-Q (filed 2023-08-03) ↗
Q4 FY2022CQ1 2023Mar 31, 2023106+26.1%Arbutus Biopharma Corp. Form 10-Q (filed 2023-05-04) ↗
Q3 FY2022CQ4 2022Dec 31, 2022116+152.3%Arbutus Biopharma Corp. Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Roivant Sciences Arbutus Biopharma Corp. (ABUS) ($M), quarterly Q1 FY2020–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/abus-mkt-row

See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?